Lv21
180 积分 2023-12-27 加入
KRAS G12C in advanced NSCLC: Prevalence, co-mutations, and testing
7小时前
已完结
Efficacy and safety of cadonilimab in previously treated recurrent or metastatic nasopharyngeal carcinoma(COMPASSION-06): A phase II multicenter study
22天前
已完结
Induction-concurrent chemoradiotherapy with or without sintilimab in patients with locoregionally advanced nasopharyngeal carcinoma in China (CONTINUUM): a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial
28天前
已完结
Adjuvant PD-1 Blockade With Camrelizumab for Nasopharyngeal Carcinoma: The DIPPER Randomized Clinical Trial
28天前
已完结
IgA nephropathy
1个月前
已完结
Atrasentan in Patients with IgA Nephropathy
1个月前
已完结
Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial
1个月前
已完结
Atrasentan in Patients with IgA Nephropathy
1个月前
已完结
Discovery of Potent and Wild-Type-Sparing Fourth-Generation EGFR Inhibitors for Treatment of Osimertinib-Resistance NSCLC
1个月前
已完结
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial
1个月前
已完结
皖公网安备34019202002308
